Sign In
Buy GH
$127.03
-3.14 (-2.41%)
At Close: Jun 03, 2026
Here's Why Guardant Health (GH) Is a Great 'Buy the Bottom' Stock Now
10:56am, Tuesday, 11'th Feb 2025
After losing some value lately, a hammer chart pattern has been formed for Guardant Health (GH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate r
Guardant Health to Participate in Upcoming Investor Conferences
07:00am, Monday, 10'th Feb 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. B
Guardant Health Announces Debt Exchange Transactions
06:30am, Friday, 07'th Feb 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 6, 2025, it entered into privately negotiated exchange ag
Are Medical Stocks Lagging Guardant Health (GH) This Year?
10:40am, Thursday, 06'th Feb 2025
Here is how Guardant Health (GH) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year.
Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
04:05pm, Thursday, 30'th Jan 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2024
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:56am, Tuesday, 28'th Jan 2025
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data showcasing th
Guardant Health Gains Medicare Coverage For Colorectal Cancer Monitoring Test
02:15pm, Tuesday, 21'st Jan 2025
On Tuesday, Guardant Health, Inc. GH announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Gu
Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone
11:51am, Tuesday, 21'st Jan 2025
Guardant Health stock hit a 13-month high Tuesday after Medicare officials agreed to pay for the company's colon cancer blood test. The post Why Top 4% Guardant Health Surged To A 13-Month High And To
PALO ALTO, Calif., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and ConcertAI, a leading oncology real-world evidence data and AI SaaS
Viz.ai to Collaborate With Guardant Health to Improve Lung Cancer Detection, Diagnosis, and Treatment
03:56pm, Tuesday, 14'th Jan 2025
SAN FRANCISCO--(BUSINESS WIRE)-- #aihealthcare--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a proposed collaboration with Guardant Health, Inc
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results
07:00am, Monday, 13'th Jan 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended Decembe
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the National Cancer Institute (NCI) has selected the company's Shield™ m
Guardant Health (GH) Soars 6.3%: Is Further Upside Left in the Stock?
05:35am, Tuesday, 07'th Jan 2025
Guardant Health (GH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increa
Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
04:05pm, Thursday, 02'nd Jan 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 43rd Annual J.P. Morgan Healt
